Optimum Patient Care Australia’s Post

The latest breakthrough research from the ISAR, as detailed in the recent publication "International Variation in Severe Exacerbation Rates in Patients With Severe Asthma” in CHEST, has unveiled an interesting landscape of variability in severe asthma exacerbation rates across diverse countries. Read the full press release: https://lnkd.in/ezM-R7Am Read the full article here: https://lnkd.in/eYWZfQDc #ResearchInRealLife #SevereAsthma #Asthma #Research

The latest breakthrough research from the ISAR, as detailed in the recent publication "International Variation in Severe Exacerbation Rates in Patients With Severe Asthma” in CHEST, has unveiled an interesting landscape of variability in severe asthma exacerbation rates across diverse countries. Read the full press release: https://lnkd.in/ezM-R7Am Read the full article here: https://lnkd.in/eYWZfQDc #ResearchInRealLife #SevereAsthma #Asthma #Research

👏Great news! Submission deadline extended to 26 July 2024! Welcome more submissions! 💡 Special Issue "Diagnosis and Management of Chronic Obstructive Pulmonary Disease (#COPD) ", led by Dr. Juan Luis Rodriguez Hermosa. 🧐The aim of this Special Issue is to gather articles focused on improving the diagnosis of COPD, as well as advances in the treatment of this disease, which consider both pharmacological and non-pharmacological interventions. 📨Website and submission link: https://lnkd.in/gBRjwBke #ChronicObstructivePulmonaryDisease #Pulmonary #lung #COPD #treatment #diagnosis #pharmacological Journal of Clinical Medicine (JCM) MDPI

Today is #WorldAsthmaDay, organized by Global Initiative for Asthma. Asthma affects over 260m people globally, about 3% of the population! VIDA is proud to provide quantitative imaging analysis for #SARP and many commercial clinical trials, with a goal to accelerate the approval of new therapies to those suffering with asthma. If you missed our webinar with pulmonologist and asthma luminary Mario Castro, MD, here are some highlight clips: https://hubs.la/Q02wphpG0 #asthma #digitalbiomarkers

We recently updated our white paper ‘Application of Breath VOCs in Asthma’ which provides an overview of the clinical applications of VOCs in asthma in relation to currently available alternatives. 🌬️ 🌐The whitepaper highlights VOCs that can reflect the type of immunological process that underlies inflammation in asthma, as well as predict exacerbations, and monitor treatment response. You can download our updated whitepaper for free here: https://ow.ly/gnS350T3YCc #asthma #biomarkers #exacerbation

2024 World Pulmonary Hypertension Day World Pulmonary Hypertension Day is an annual global event to raise awareness of pulmonary hypertension, a severe condition affecting the lungs and heart. PHA Europe spearheads the 2024 World PH Day campaign with the theme “United for,” focused on five pivotal elements of living with PH: early diagnosis, hope, access to care, patient support and the pursuit of a cure

The rising prevalence of obesity and increasing strain on hospitals and clinics have highlighted the need for innovative treatments for cardiometabolic diseases. As research and development in GLP1-RAs and other cardiometabolic treatments continues to evolve, so does the opportunity to enable at-home care with autoinjectors. Over the past decade, SHL Medical has spearheaded numerous device projects, especially in the cardiometabolic disease area. Many of these combination product launches have relied on SHL Medical’s Molly® modular platform autoinjectors, which played a crucial role in the approval of second-generation GLP1-RAs for T2D in Japan in 2020 and for obesity in the US in the 2021. Join me in this exclusive webcast where I’ll delve further on SHL Medical and Molly’s contributions in powering the next wave of cardiometabolic care. Register to access the video: https://lnkd.in/dkjuGZTC #CardiometabolicCare #DrugDelivery #ThoughtLeadership

🔬 Exploring GERD: Understanding Gastroesophageal Reflux Disease 🔬 At MedTraits NY, we're dedicated to shedding light on common medical conditions to empower our community with knowledge and understanding. Today, let's delve into Gastroesophageal Reflux Disease (GERD). GERD occurs when stomach acid regularly flows back into the esophagus, causing discomfort and potentially leading to complications if left untreated. From heartburn and regurgitation to chest pain and difficulty swallowing, GERD symptoms can significantly impact one's quality of life. Our clinical research team at MedTraits NY is committed to advancing the understanding and treatment of GERD through innovative research initiatives. By collaborating with leading experts and employing state-of-the-art methodologies, we strive to enhance therapeutic options and improve patient outcomes. #MedTraitsNY #ClinicalResearch #GERD #HealthcareInnovation #empoweringcommunities

🌟 At AstraZeneca , we're not just advancing medicine; we're transforming lives. By integrating #AI with home spirometry, we aim to bring early diagnosis and monitoring of respiratory diseases right to your doorstep. It's innovation with purpose.💡 #RespiratoryHealth #AIInnovation

✨ New article sharing in April! Welcome to read, share and download this original article! Title: Small airway disease assessed by parameters of small airway dysfunction in patients with asthma, asthma-chronic obstructive pulmonary disease-overlap, and chronic obstructive pulmonary disease ✍ Authors: Richard Kraemer, Heinrich Matthys In the study, Authors evaluated the role of several spirometric and plethysmographic parameters defining SAD within three diagnostic groups (asthma, ACO, and COPD) to elaborate potential discriminating functional and/or treatable traits in an optimized concept of precision medicine. 🔎 Keywords: #Asthma, #chronic obstructive pulmonary disease, #asthma-COPD overlap, #small airway disease, #small airway dysfunction, #pulmonary hyperinflation, #aerodynamic resistive work of breathing at rest Read online at https://lnkd.in/gxxT2aMP Download PDF at https://lnkd.in/gKrucnZE